2022
An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach: Analysis of Data From a Tertiary Care Medical Center.
Wang JD, Sebastian C, Walther Z, Suresh T, Lacy J, Zhang X, Jain D. An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach: Analysis of Data From a Tertiary Care Medical Center. Archives Of Pathology & Laboratory Medicine 2022, 147: 185-192. PMID: 35512224, DOI: 10.5858/arpa.2021-0457-oa.Peer-Reviewed Original ResearchConceptsLiver biopsyUnknown primaryIHC markersPrimary siteTrue carcinomaTertiary care medical centerAvailable clinicopathologic dataSquamous cell carcinomaClinicopathologic dataHepatic metastasesNonepithelial tumorsCell carcinomaInstitutional databaseClinical managementStain usePractice patternsNeuroendocrine neoplasmsImmunohistochemical markersMedical CenterMorphologic patternsIndividualized approachCarcinomaBiopsyMetastasisTumors
2014
Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.
Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.Peer-Reviewed Original Research